Hear directly from Dr. Anastasios Manessis in a one-on-one interview about his experience using retinal AI screening and his candid thoughts on the technology.

{Timeline}
00:00 ~ 05:08 The Importance of Retinal Exams in Patients with Diabetes
05:08 ~ 11:40 Limitations of Traditional Cardiovascular Risk Assessment
11:40 ~ 14:29 First Impressions and Advantages of Retinal Image-Based Risk Assessment
15:35 ~ 18:04 A Real-World Patient Case
19:36 ~ 20:49 Which Patient Groups Are Most Commonly Identified?
23:57 ~ 25:14 Improving Patient Adherence and Encouraging Follow-Up Testing
26:11 ~ 29:39 Requirements for Clinical Adoption and Broader Implementation
33:03 ~ 35:08 Upcoming Research Presentation and Future Implications

ℹ️ Dr. Manessis is a double board-certified physician at Endocrine Associates of West Village PC, with practices in Murray Hill, Manhattan, and Long Island City, New York. He specializes in endocrinology, diabetes, metabolism, and obesity medicine.

ℹ️ Dr. Noon CVD is a world’s first commercialized AI-powered solution utilizing retinal imaging to assess cardiovascular risk. It is used by 170+ medical institutions worldwide, supporting clinicians with cardiovascular risk insights. It is an investigational service, not currently cleared or approved by the U.S. FDA. The technologies described are presented for research and informational purposes only and are not intended for clinical diagnostic use.

www.mediwhale.com